

Molecular Profiling Requisition – Peru



Phone: 00 41 21 533 53 00 | Fax: 00 41 21 533 53 01 | Email: InternationalSupport@CarisLS.com.

Please complete and return by fax or email. Incomplete or missing data may result in delayed testing.

TREATING ONCOLOGIST INFORMATION			PATIENT INFORMATION						
Name		Caris Account Number/ Distributor		Last Name		First Name		MI	
Physician Email		Office Contact Name		In-Office Medical Record Number		DOB (DD/MM/YYYY)		Biological Sex ☐ M ☐ F	
Office/Hospital Name		Address		Address		Apt.			
City		Country		Postal Code		City		Country	
Phone		Fax		Mobile Phone		Email			

PATHOLOGY INFORMATION			
Pathology Services/Specimen Storage Location		Address/Suite	
City		Country	
Phone		Fax	
		Postal Code	

BILLING INFORMATION	
☐ Self-pay: Payment is required before testing starts. Caris Customer Support will contact the patient directly to agree payment terms.	
☐ Health Insurance: A reimbursement request has been sent to patient's health insurance.	
Insurance Company: _____ Policy #: _____ Pre-Authorization / Authorization #: _____ (if available)	
☐ Hospitals/Clinics: Institution will be billed after testing has been performed.	
☐ Other, please specify: _____	

CLINICAL/SPECIMEN INFORMATION (Include a copy of the pathology report and medical records that support the need for testing.)					
Diagnosis (Provide as many symptomatic diagnosis codes as applicable)			Primary Tumor Site		Clinical Stage ☐ I ☐ II ☐ III ☐ IV
					Most Recent Tissue Specimen ☐ Yes ☐ No
TISSUE-BASED TESTING	Specimen Collection Location (Place of Service)		Specimen Type(s) ☐ Formalin Fixative ☐ FFPE Block ☐ Unstained Slides		BLOOD-BASED TESTING
	☐ Hospital Inpatient: Discharge Date _____		Specimen Collection Location (Place of Service)		
	☐ Hospital Inpatient, Not Yet Discharged		☐ Hospital Inpatient: Discharge Date _____		
	☐ Hospital Outpatient: Discharge Date _____		☐ Hospital Inpatient, Not Yet Discharged		
	☐ Office/ASC		☐ Hospital Outpatient: Discharge Date _____		
☐ Other: _____		Specimen ID#(s)		☐ Office/ASC	
Facility Name Where Procedure Performed/Collected		Collection Date & Time (DD/MM/YYYY)		☐ Other: _____	
		Date Removed from Storage (DD/MM/YYYY)		Facility Name Where Procedure Performed/Collected	
				Specimen Type ☐ Whole Blood	
				Sample Draw ☐ Venous ☐ Port	
				Collection Date & Time (DD/MM/YYYY)	

MOLECULAR PROFILING TESTING OPTIONS (See reverse side for test descriptions and specimen requirements.)		
SOLID TUMOR TISSUE TESTING		SOLID TUMOR BLOOD TESTING
MI Profile™ Comprehensive Testing ☐ MI Tumor Seek Hybrid™ + IHCs and Other Tests by Tumor Type ☐ Include Caris GPSai™ reporting for cancer type similarity assessment		Next-Generation Sequencing ☐ Caris Assure® ☐ Exclude incidental germline results ☐ Exclude DPYD results Does the patient have a history of hematologic malignancy, MDS, bone marrow/stem cell/solid organ transplant? ☐ Yes, please specify: _____ ☐ No
Next-Generation Sequencing Only ☐ MI Tumor Seek Hybrid™ (LDT) ☐ Add MGMT by pyrosequencing for glioma cases ☐ Include Caris GPSai™ reporting for cancer type similarity assessment		

Concurrent Testing ☐ I certify that ordering concurrent tissue- and blood-based profiling will assist me in treating my patient and is medically necessary based on several clinical factors, which may include, oncology guidelines support concurrent testing in this disease state, turnaround time for tissue-based testing may delay important treatment decisions, or the available tissue may not meet testing requirements, among others. Additionally, I will provide any medical records necessary to support concurrent testing.
--

MEDICAL NECESSITY / SPECIAL INSTRUCTIONS / ADDITIONAL CC PHYSICIAN CONTACT INFORMATION

ATTESTATION & PATIENT CONSENT
This requisition constitutes an order for molecular testing from Caris MPI, Inc. (Caris) I certify (a) the services are medically necessary and will assist me in treating my patient, (b) the patient has sufficient performance status to receive additional treatment, (c) I will make available patient medical records documenting the foregoing, and (d) I supplied information to the patient regarding this testing, explained the purpose of this testing to the patient, and obtained informed consent for (i) such testing, (ii) any analysis and reports related to such testing, (iii) Caris to retain testing results, samples and related information and analysis, (iv) Caris' use or disclosure (including to third parties) of deidentified information generated from such testing for general research and other purposes, (v) Caris' disclosure of testing results and information to third-party payers in connection with such testing, and (vi) for Caris to contact the patient regarding the testing.
Authorized Provider Signature:
Provider Name (Print):
Date (DD/MM/YYYY):

FINAL REPORT WILL BE DELIVERED IN ENGLISH. PLEASE SEE THE REVERSE FOR PATIENT CONSENT REQUIREMENTS AND OPTIMAL SPECIMEN REQUIREMENTS. TERMS AND CONDITIONS APPLY.

Test Descriptions

The biomarkers included in the options below may change from time to time. Before ordering, please refer to www.CarisLifeSciences.com to view intended use and the definitive list of available biomarkers and the specific biomarkers analyzed by tumor type.

TISSUE	MI Profile™ <i>Comprehensive Testing</i>	MI Tumor Seek Hybrid™ + IHCs and Other Tests by Tumor Type. Tissue-based Whole Exome and Whole Transcriptome Sequencing analysis, plus additional tumor-type relevant biomarker testing (IHC, ISH, etc.). Caris FOLFIRSTai™ is performed for mCRC cases and Caris GPSai™ is performed for CUP cases. MGMT by pyrosequencing for glioma cases can be added to results.
	MI Tumor Seek Hybrid™ (LDT) <i>Next-Generation Sequencing</i>	MI Tumor Seek Hybrid™ is a NGS-based laboratory-developed test that uses WES/WTS to analyze DNA and RNA extracted from tumor tissue to detect multiple types of genomic alterations. Caris FOLFIRSTai™ is performed for mCRC cases and Caris GPSai™ is performed for CUP cases. MGMT by pyrosequencing for glioma cases can be added to results.
	Caris GPSai™	Caris GPSai™ is a cancer type similarity assessment intended to help identify tumor of origin by matching a tumor's molecular signature to the Caris genomic and transcriptomic database.
	Caris FOLFIRSTai™	Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment.
BLOOD	Caris Assure®	Blood-based Whole Exome and Whole Transcriptome Sequencing for pathogenic and likely pathogenic tumor-derived, incidental CH variant detection. Caris Assure® is intended for patients with previously diagnosed solid malignant neoplasms when tissue is not feasible and is to be used by qualified healthcare professionals. RNA results are intended for investigational purposes only. Not a replacement for comprehensive germline testing. Incidental pathogenic alterations are reported, including ACMG recognized cancer genes. Negative results do not imply the patient does not harbor a germline mutation. Not intended for patients with a history of bone marrow, stem cell, or solid organ transplant.

Specimen Requirements for Next-Generation Sequencing

SPECIMEN TYPE	SPECIMEN REQUIREMENTS
Tissue	MI Profile™: 20% tumor nuclei, TNA extraction with ≥25 ng of DNA, Formalin-based fixatives preferred, Non-decalcified tissue preferred MI Tumor Seek Hybrid™ (LDT): 20% tumor nuclei, TNA extraction with ≥25 ng of DNA, Formalin-based fixatives preferred, Non-decalcified tissue preferred
Blood	Caris Assure®: Two (2) 10 mL tubes of whole blood, PAXgene® Blood ccfDNA tubes only

Formalin Fixed Paraffin Embedded (FFPE) Samples

Sufficient tumor (≥ 20% tumor nuclei) must be present to complete all analysis. If you have any questions, please contact Customer Support at 00 800 12 12 30 30.

SPECIMEN TYPE	SPECIMEN REQUIREMENTS
Fixed Tissue	One (1) tumor-containing formalin fixed paraffin embedded block (FFPE) from most recent surgery or biopsy. Successive four (4) micron sections will be created from the block until sufficient material for the testing orders is obtained. For the molecular analysis, tumor cells will be excised by microdissection.
Unstained Slides	Unstained, positively charged, unbaked slides from one single, tumor-containing formalin fixed paraffin embedded block; 4 micron sections. Tumor content: ≥20% tumor nuclei MI Tumor Seek Hybrid™ (LDT): 10 slides; 25 slides if ordering additional tumor-specific testing (IHC, ISH, etc.) Note: Specimens with a smaller tumor area may require additional specimen to be submitted.
Core Needle Biopsy	Four to six (4-6) biopsies with 18 gauge needle preferred. Six to ten (6-10) biopsies with 22 gauge needle accepted. (Preparation in 10% neutral buffered formalin.)
Fine Needle Aspirate (FNA)	One (1) formalin fixed paraffin embedded block containing sufficient tumor. Please do NOT use non-formalin-based fixatives, including alcohol-based fixatives.
Malignant Fluid Cell Block	One (1) formalin fixed paraffin embedded cell block containing sufficient tumor (≥20% tumor nuclei). Please do NOT use non-formalin-based fixatives, including alcohol-based fixatives.
Bone/Bone Metastasis	One (1) formalin fixed paraffin embedded block of tumor (primary bone malignancy or metastasis to the bone) decalcified using EDTA based method(s) or non-decalcified specimen.

Fresh Sample

Sufficient tumor must be present to complete all analysis.

SPECIMEN TYPE	SPECIMEN REQUIREMENTS
Whole Blood	Two (2) 10 mL PAXgene® Blood ccfDNA tubes of whole blood. Invert 10x. Do not shake. Do not freeze. Ship room temperature.

Insufficient Specimen Quantity – Prioritization of Tests

In the event that a specimen is received with an insufficient quantity of tissue or insufficient percent of tumor required to perform the entire profile or individual tests indicated on the requisition, the Caris pathologist will prioritize and order the appropriate testing unless otherwise indicated by the ordering physician.

Important Treatment Note

The results for biomarkers tested under this requisition will be provided in a report associating one or more treatment agents to biomarkers based on published medical evidence, which may include published studies performed in the tumor type present in the tested sample or derived from a different tumor type. Decisions regarding care and treatment should not be based solely on selection of a test such as this test or the information provided related to this requisition. Decisions on patient care and treatment must be based on the treating physician's independent medical judgment, taking into consideration all relevant patient information, such as family history, physical examinations, results of other diagnostic tests, and patient preferences, and in accordance with the applicable standard of care. The selection of any or none of the matched agents is ultimately and solely in the discretion of the treating physician. Physician or practitioner hereby acknowledges and agrees to comply with any local, state/provincial, or national laws or regulations, rules or order of any governmental body, having jurisdiction over activities considered under this requisition.